180 Life Sciences Corp
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | (Deficit) | |
| Balance - January 1, 2023 | 197,209 | $20 | $121,637,966 | $(2,885,523) | $(107,408,545) | $11,343,918 |
| Adjustment related to reverse stock split | 37 | 1 | (1) | - | - | - |
| Shares issued for professional services to directors | 4,763 | - | 60,624 | - | - | 60,624 |
| Shares issued for professional services to executive chairman | 7,126 | 1 | 28,564 | - | - | 28,565 |
| Issuance of April 2023 pre-funded and common warrants, net (a) | - | - | 2,337,706 | - | - | 2,337,706 |
| Shares issued from exercise of April 2023 pre-funded warrants (a) | 61,615 | 6 | 111 | - | - | 117 |
| Shares issued in connection with April 2023 Offering (a) | 21,053 | 2 | 382,180 | - | - | 382,182 |
| Issuance of August 2023 pre-funded and common warrants, net (b) | - | - | 2,459,282 | - | - | 2,459,282 |
| Shares issued from exercise of August 2023 pre-funded warrants (b) | 207,814 | 20 | 375 | - | - | 395 |
| Shares issued in connection with August 2023 Offering (b) | 35,102 | 4 | 245,344 | - | - | 245,348 |
| Issuance of pre-funded and common warrants from Amendment to August 2023 SPA, net | - | - | 770,923 | - | - | 770,923 |
| Stock-based compensation | - | - | 2,194,135 | - | - | 2,194,135 |
| Comprehensive loss: | ||||||
| Net loss | - | - | - | - | (19,935,112) | (19,935,112) |
| Other comprehensive loss | - | - | - | (15,816) | - | (15,816) |
| Balance - December 31, 2023 | 534,719 | $54 | $130,117,209 | $(2,901,339) | $(127,343,657) | $(127,733) |
| (a) | Consists of $2,999,882 of gross proceeds from the April 2023 Offering; gross proceeds of $421,527 are related to common shares issued (with related placement agent fees of $39,343), gross proceeds of $1,233,564 are related to pre-funded warrants issued (with related placement agent fees of $115,134) and gross proceeds of $1,344,791 are related to common warrants issued (with related placement agent fees of $125,516). At the end of the current period, all 61,615 April 2023 pre-funded warrants were exercised for proceeds of $117. |
|---|---|
| (b) | Consists of $2,999,605 of gross proceeds from the August 2023 Offering; gross proceeds of $272,106 are related to common shares issued (with related placement agent fees of $26,758), gross proceeds of $1,449,470 are related to pre-funded warrants issued (with related placement agent fees of $142,538) and gross proceeds of $1,278,029 are related to common warrants issued (with related placement agent fees of $125,679). At the end of the year, 207,814 August 2023 pre-funded warrants were exercised for proceeds of $395. |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY, continued
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance - January 1, 2022 | 89,569 | $9 | $107,187,532 | $817,440 | $(68,682,286) | $39,322,695 |
| Adjustments related to reverse stock-split | 505 | - | - | - | - | - |
| Issuance of July 2022 pre-funded warrants (c) | - | - | 2,562,265 | - | - | 2,562,265 |
| Shares issued from exercise of July 2022 pre-funded warrants (c) | 6,297 | 1 | 262 | - | - | 263 |
| Shares issued in connection with July 2022 Offering (c) | 9,211 | 1 | 3,407,489 | - | - | 3,407,490 |
| Issuance of December 2022 pre-funded warrants | - | - | 4,823,187 | - | - | 4,823,187 |
| Shares issued from exercise of December 2022 pre-funded warrants | 78,910 | 8 | 142 | - | - | 150 |
| Shares issued in connection with December 2022 Offering | 11,316 | 1 | 691,672 | - | - | 691,673 |
| Shares issued for professional services to directors | 739 | - | 331,591 | - | - | 331,591 |
| Stock-based compensation | 32 | - | 2,633,826 | - | - | 2,633,826 |
| Comprehensive loss: | ||||||
| Net loss | - | - | - | - | (38,726,259) | (38,726,259) |
| Other comprehensive loss | - | - | - | (3,702,963) | - | (3,702,963) |
| Balance - December 31, 2022 | 197,209 | $20 | $121,637,966 | $(2,885,523) | $(107,408,545) | $11,343,918 |
| (c) | Consists of $6,499,737 of gross proceeds from the July 2022 Offering; gross proceeds of $3,710,000 are related to the common shares and common warrants issued and includes $302,510 in related placement agent fees and other offering costs, and $2,789,737 in gross proceeds are in connection with the pre-funded warrants and includes $227,472 in related placement agent fees and other offering costs. At the end of the period, 81,426 July 2022 pre-funded warrants were exercised for proceeds of $155. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.